Penn Davis Mcfarland Inc. Has $258,000 Position in Amgen Inc. (AMGN)

Penn Davis Mcfarland Inc. held its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,500 shares of the medical research company’s stock at the end of the second quarter. Penn Davis Mcfarland Inc.’s holdings in Amgen were worth $258,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. TrimTabs Asset Management LLC increased its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC increased its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares in the last quarter. American Beacon Advisors Inc. acquired a new position in Amgen during the first quarter worth about $106,000. Finally, Nelson Roberts Investment Advisors LLC acquired a new position in Amgen during the first quarter worth about $121,000. 79.12% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.64% during mid-day trading on Monday, reaching $168.36. 616,944 shares of the company traded hands. The stock’s 50-day moving average is $174.04 and its 200-day moving average is $168.05. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21. The company has a market capitalization of $122.85 billion, a P/E ratio of 15.33 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.84 earnings per share. On average, equities analysts predict that Amgen Inc. will post $12.57 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be given a dividend of $1.15 per share. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.74%. Amgen’s payout ratio is 41.93%.

ILLEGAL ACTIVITY NOTICE: “Penn Davis Mcfarland Inc. Has $258,000 Position in Amgen Inc. (AMGN)” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://transcriptdaily.com/2017/08/21/penn-davis-mcfarland-inc-has-258000-position-in-amgen-inc-amgn.html.

A number of research analysts recently issued reports on AMGN shares. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $189.00 target price on shares of Amgen in a research report on Friday, June 30th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC restated a “hold” rating and set a $180.00 target price on shares of Amgen in a research report on Monday, May 22nd. Credit Suisse Group set a $177.00 target price on shares of Amgen and gave the company a “hold” rating in a research report on Friday, July 14th. Finally, Morgan Stanley boosted their target price on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. Amgen currently has an average rating of “Buy” and an average target price of $186.04.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.20% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply